Search - tctmd.com

Displaying 1 - 20 of 79

Sort: Relevancy | Date

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Opinion CV Team Dispatch

February 2025 Dispatch for the CV Team

L.A. McKeown

February 01, 2025

News Daily News

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

L.A. McKeown

January 31, 2025

News Daily News

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

Michael O'Riordan

August 26, 2024

News Daily News

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

L.A. McKeown

August 19, 2024

News Daily News

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Yael L. Maxwell

August 16, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2024

Shelley Wood

July 31, 2024

News Daily News

Apixaban May Have Advantages in Patients With Liver Cirrhosis and AF

Michael O'Riordan

July 09, 2024

News Daily News

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

L.A. McKeown

February 23, 2024

News Daily News

Low Bleeding Profile With Asundexian Seen in Pooled Analysis

L.A. McKeown

February 13, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2023

Shelley Wood

November 30, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

L.A. McKeown

November 12, 2023

News Opinion Editor's Corner AHA 2023

What’s Going to Be Hot at AHA 2023

Shelley Wood

November 07, 2023

News Daily News

First Drugs Chosen for Medicare Negotiations Hit Close to Home for Cardiologists

L.A. McKeown

August 31, 2023

News Conference News ESC 2023

FRAIL-AF: Warfarin Beats NOACs in Frail Elderly With AF

Shelley Wood

August 28, 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2023

Shelley Wood

May 31, 2023

News Conference News EuroPCR 2023

ADALA: Low-Dose Apixaban Tops DAPT After LAA Closure

Todd Neale

May 18, 2023

News Opinion Editor's Corner ACC 2023

What’s Going to Be Hot at ACC/WCC 2023?

Shelley Wood

February 27, 2023

News Daily News

OSCAR Supports Rivaroxaban for Secondary VTE Prevention in Cancer

L.A. McKeown

December 16, 2022

News Daily News

Apixaban Again Linked to Less Bleeding in AF Patients

Michael O'Riordan

October 31, 2022

Advertisement

What’s Going to Be Hot at ACC 2025?

February 2025 Dispatch for the CV Team

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

CMS Announces Negotiated Medicare Prices for First 10 Drugs

TCTMD’s Top 10 Most Popular Stories for July 2024

Apixaban May Have Advantages in Patients With Liver Cirrhosis and AF

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

Low Bleeding Profile With Asundexian Seen in Pooled Analysis

TCTMD’s Top 10 Most Popular Stories for November 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

What’s Going to Be Hot at AHA 2023

First Drugs Chosen for Medicare Negotiations Hit Close to Home for Cardiologists

FRAIL-AF: Warfarin Beats NOACs in Frail Elderly With AF

TCTMD’s Top 10 Most Popular Stories for May 2023

ADALA: Low-Dose Apixaban Tops DAPT After LAA Closure

What’s Going to Be Hot at ACC/WCC 2023?

OSCAR Supports Rivaroxaban for Secondary VTE Prevention in Cancer

Apixaban Again Linked to Less Bleeding in AF Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content